Loosening Medicaid best price restrictions on value-based contracts could increase drug spending by making it easier for drug companies to use bundled contracts in the commercial market, according to West Health Policy Center Health Policy Director Sean Dickson. Drug makers say the best price rule impedes value-based arrangements with insurers, but Medicaid law already exempts pharmacy benefit manager rebates, which are the primary means of paying for performance, from best price rules. The drug industry touts value-based pay as a...